J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.

Slides:



Advertisements
Similar presentations
OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.
Advertisements

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
Stone p2203/Abstract/ Conclusions
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
BIFURCATION LESIONS Dr. Tahsin.N
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
APPOSITION II study results Robert-Jan van Geuns, MD On behalf of the APPOSITION II Investigators.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Disrupt CAD Study Design
My initial ABSORB experience Assoc. Prof. I. Petrov
New Generation Resolute Integrity Drug-Eluting Stent Superior to Benchmark Xience Drug-Eluting Stent: Primary Endpoint Results from the PROPEL Study –
on behalf of the ABSORB II Investigators
(DES)+BVS +DCB for long diffuse LAD disease
The Tryton Bifurcation Trial:
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
BVS Expand: First Results of Wide Clinical Applications
Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.
On behalf of J. Belardi, M. Leon, L. Mauri,
Study Design AMI <12 hours, any age, cardiogenic shock excluded
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
TAXUS II and IV: two-year follow-up
SKS Technique Clinical Case
American College of Cardiology Presented by Dr. Stephan Windecker
European Society of Cardiology 2003
REALITY: 8 month results
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
Presented at ACC 2003 Late Breaking Clinical Trials
Published in the European Heart Journal
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Drug-eluting stents for in-stent restenosis
ENDEAVOR II Five-Year Clinical Follow-up
TAXUS – Myonecrosis and sidebranch patency concerns are short-term issues with no long-term consequences, and the benefits are undeniable Jeffrey J. Popma,
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Elevated Admission Plasma Glucose Following ACS
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille

Mr L; 60 ans Infarcus ant H 4

Pre dilatation IVA et Diag ballon 2.5 x 15

IMPLANTATION du STENT 2.5/3 x 22 mm

OUVERTURE DES MAILLES et CONTROLE FINAL sans post-dilatation ni kissing

CONTRÔLE à J30 avant Angioplastie CX

ANGIOGRAPHIE QUANTITATIVE J O : Ref 2.96 Sténose: 2.56 mm J 30: Ref 3.25 Sténose 2,9 mm

APPOSITION III trial DESIGN Prospective, non-randomized, single-arm, multi-center study of the STENTYS Coronary Stent OBJECTIVE Evaluate safety and performance of the STENTYS stent, in routine clinical practice in 1000 STEMI patients PRIMARY ENDPOINT MACE at 12 months (MACE defined as cardiac death, target vessel re-MI, emergent CABG, or clinically-driven TVR by percutaneous or surgical methods at 12 months) SECONDARY ENDPOINTS MACE at 30 days and 24 months Target vessel failure at 30 days and 24 months Reperfusion measured by TIMI Flow, ST elevation resolution Incidence of stroke at 30 days, 12 and 24 months Stent thrombosis at 30 days, 12 and 24 months Abrupt closure of Side Branch >2.25 mm (TIMI<3) 1000 patients 600 patients interim analysis Clinical follow-up at 1 month

Stent characteristics N=600 Total number of stents implanted / patient 1.2 ±0.4 STENTYS BMS/ DES (%)82 / 18 Small size (%): mm6 Medium size (%): mm46 Large size (%): mm47 22 mm length (%)56 27 mm length(%)43 Bifurcation lesion 13% Stent disconnection performed (%) 2% Second stent used at target lesion (%) 21 STENTYS stent8 Other stent13 9

Procedure guidelines Recommendation to perform thrombo-aspiration Recommendation to perform thrombo-aspiration Pre-dilatation left to the discretion of the operator Pre-dilatation left to the discretion of the operator Overlapping stents allowed Overlapping stents allowed Treatment of other lesions in the target vessel is allowed Treatment of other lesions in the target vessel is allowed Side Branch treatment left to the discretion of the operator; ‘disconnection’ of STENTYS stent to create SB-access Side Branch treatment left to the discretion of the operator; ‘disconnection’ of STENTYS stent to create SB-access Post-dilatation Post-dilatation  Cohort A (pt 1-390): recommended for residual stenosis >30%  Cohort B (pt ): generally recommended High pressures are generally not needed due to the self- expanding properties of the STENTYS stent High pressures are generally not needed due to the self- expanding properties of the STENTYS stent Medication according to ESC and local guidelines Medication according to ESC and local guidelines

Pre- and post-dilatation N=600 Pre-dilatation performed (%) 53.1 Mean Maximal pressure (atm) 13.1 ±3.7 Balloon diameter (mm) 2.6 ±0.5 Post-dilatation performed (%)62.9 Mean Maximal pressure (atm) 15.1 ± 4.1 Balloon diameter (mm) 3.4 ±

MACE at 30 days (cohort analysis) Cohort A N=390 Cohort B N=210 Cardiac death32 Re-MI72 TLR81 TOTAL 18 (4.6%)5 (2.4%) 12 1 MACE: cardiac death, target vessel based re-MI, emergent bypass surgery (CABG), or clinically driven TLR Optimized pre/post dilatation results in a low rate of adverse events

Result in post-dilatation cohorts Cohort A N=390 Cohort B N=210 P Pre-dilatation performed (%) Maximal pressure (atm) Balloon diameter (mm) Post-dilatation performed (%) Maximal pressure – atm Balloon diameter – mm Pre- and post dilatation No pre- nor post dilatation Only pre-dilatation (%) Only post-dilatation (%)

COMMENTAIRES En cas de préparation efficace de la lésion, une post-dilatation ne semble pas toujours indispensable. Du fait des propriétés d’expansion du stentys,le kissing final ne parait pas nécessaire dans toutes les lésions de bifurcation.